Skip to Navigation Skip to Search Skip to Content
Search All Centers

Precision Medicine for Myeloma: Are There New Targeted Drugs in Development?

Read Transcript Download/Print Transcript

Published on December 18, 2018

Where is research today on precision medicine for multiple myeloma? Can treatments target specific genetic markers in myeloma patients? During a recent Town Meeting in Atlanta, renowned myeloma expert Dr. Jonathan Kaufman, from theWinship Cancer Institute, gives an important update on targeted therapies for myeloma and explains how treatments work to target myeloma cells on a biological level. Watch now to learn more.

This town meeting is sponsored by Amgen, Janssen Pharmaceuticals and Adaptive Biotechnologies. It is produced by Patient Power in partnership with Winship Cancer Institute of Emory University.

Featuring

Keep up the great work! You are my go-to source for the latest myeloma news.

— via email

Partners

Winship Cancer Institute

You might also like

Transcript | Precision Medicine for Myeloma: Are There New Targeted Drugs in Development?

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Jack Aiello:

And so all of these other drugs, the BCMA-targeted drugs and the anti-CD38-targeted drug are really focused on that side of the biology, which is the plasma cell biology, which leaves completely the cancer biology.  And when I say the cancer biology I talking about targeting mutations and so forth. And so that's an area where, to be frank, we've had less success in myeloma to date.  And this really gets into that other topic of precision medicine, which is we still don't have ways of looking at a single abnormal molecule in myeloma and targeting it.  

We are starting to ask those questions with looking at groups of abnormalities in like BRAF and RAS and so forth, and we had a drug up there earlier, but we're really somewhat behind in that aspect. There's a lot of drugs that are targeted, a lot of molecules that are targeted, but one of the other challenges in targeting myeloma is that across patients myeloma is different, within patients myeloma is different.   

And so every myeloma cell in the body doesn't share these targets, and so we haven't??and so the future very much is going to be a combination of targeting the plasma cell biology along with targeting the more cancer biology where we can have specific targets and possible multiple targets within that cancer biology.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.